Sanofi’s dengue vaccine rolled out for world’s first public immunisation program
April 4, 2016Sales and Marketing Philippines, Sanofi, Vaccine, children, dengue, dengvaxia, immunisation, prevention, public health
Sanofi, along with its vaccines global business unit Sanofi Pasteur, has announced the beginning of the first public dengue immunisation …
Daiichi Sankyo names Antoine Yver global head of oncology research and development
April 1, 2016Business Services, Medical Communications Daiichi Sankyo, Japan, appointment
Japanese drug major Daiichi Sankyo (TYO: 4568) on Friday named Antoine Yver, global head, oncology research and development, effective April …
Pfizer’s cholesterol-lowering bococizumab shows promise in Phase III trials
April 1, 2016Research and Development, Sales and Marketing Pfizer, bococizumab, lipid, phase 3, phase III, spire, spire-ai
Pfizer (NYSE: PFE) has announced positive top line results from the SPIRE-AI Phase III clinical trial evaluating bococizumab. This protein …
FTC files complaint against Endo for blocking generics of its pain drugs
April 1, 2016Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing Endo International, FTC, legal, regulation
The US Federal Trade Commission (FTC) has filed a complaint against Endo International (Nasdaq: ENDP) alleging the company used illegal …
FDA to review investigational hepatitis B vaccine
April 1, 2016Medical Communications, Research and Development dynavax, hepatitis B, vaccines
Dynavax Technologies (NASDAQ: DVAX) says the FDA has accepted for review the company’s investigational adult hepatitis B vaccine, HEPLISAV-B. The FDA has set …
Whistleblower accuses Novartis of paying bribes in Turkey to push sales
April 1, 2016Business Services, Medical Communications, Sales and Marketing Financial, Novartis, legal, reuters
An anonymous whistleblower has accused Swiss drugmaker Novartis (SIX: NOVN) of paying bribes in Turkey through a consulting firm to …
Janssen to stop fulranumab development in osteoarthritis pain
April 1, 2016Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen
Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain. The J&J company says the decision is …
Fake press release on drug pricing “erroneously attributed” to Pfizer
April 1, 2016Medical Communications Pfizer, fake, false, legal action, press release, washington post
Pfizer (NYSE: PFE) has issued a statement on a false press release related to drug pricing that was reported on …
FDA releases biosimilars labelling guidance
April 1, 2016Manufacturing and Production, Medical Communications, Research and Development FDA, biosimilars
The US Food and Drug Administration (FDA) has issued draft guidance on the labelling of biosimilar drugs. The guidance states …
Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment
April 1, 2016Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
Samsung Bioepis’ Remicade biosimilar set for CHMP verdict
March 31, 2016Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab
Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …
Lilly’s RA drug baricitinib meets Phase III goals
March 31, 2016Research and Development Eli Lilly, Incyte, rheumatoid arthritis
Eli Lilly and Incyte have announced the publication of detailed Phase III trial results from a study of their biologic …
GSK introduces new measures to widen medicines access in poorest countries
March 31, 2016GSK has set out a series of measures it is introducing to help improve access to the company’s innovative medicines …
Shire hikes CEO pay to £15 million
March 31, 2016Business Services, Sales and Marketing
UK drug major Shire (LSE: SHP) has raised the compensation for the chief executive Flemming Ornskov to £15 million for …
Jazz Pharmaceuticals receives FDA approval for rare veno-occlusive disease treatment
March 31, 2016Research and Development, Sales and Marketing FDA, jazz pharmaceuticals
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Defitelio …
Actinium gets Orphan Drug Designation for myeloid leukaemia drug
March 31, 2016Research and Development Actinium Pharmaceuticals
New York-based biopharma Actinium Pharmaceuticals (NYSE MKT: ATNM) has received orphan drug designation from the US FDA for Iomab-B, a …
Janssen-Cilag’s HIV treatment gets NHS backing
March 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial
Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV. The company said following the …
Roche to initiate testing for Zika virus under FDA investigational new drug application approval
March 31, 2016Manufacturing and Production, Research and Development Roche, Zika
Roche (SWX: RO) has announced that the US Food and Drug Administration (FDA) has provided approval to initiate the collection …
Bio Products Laboratory gets European approval for bleeding disorder treatment
March 30, 2016Research and Development, Sales and Marketing Bio Products Laboratory, Coagadex, human coagulation factor X
UK-based Bio Products Laboratory has received marketing authorisation from the European Medicines Agency for Coagadex – a drug which treats …
Biogen appoints Michel Vounatsos executive vice president, chief commercial officer
March 30, 2016Research and Development, Sales and Marketing
Biogen has appointed Michel Vounatsos as executive vice president and chief commercial officer, from April 18, 2016. Vounatsos will oversee …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
